4//SEC Filing
Lee Jennifer Kayden 4
Accession 0001104659-25-011677
CIK 0001649904other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 9:46 PM ET
Size
22.8 KB
Accession
0001104659-25-011677
Insider Transaction Report
Form 4
Lee Jennifer Kayden
EVP, Head of North America
Transactions
- Exercise/Conversion
Common Stock
2025-02-09$6.80/sh+4,189$28,485→ 8,598 total - Sale
Common Stock
2025-02-11$57.50/sh−4$230→ 5,413 total - Exercise/Conversion
Restricted Stock Units
2025-02-11−2,031→ 0 total→ Common Stock (2,031 underlying) - Exercise/Conversion
Common Stock
2025-02-09+3,437→ 4,409 total - Sale
Common Stock
2025-02-11$57.51/sh−1,023$58,833→ 5,417 total - Sale
Common Stock
2025-02-10$58.39/sh−1,894$110,596→ 6,704 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-02-09−4,189→ 21,601 totalExercise: $6.80Exp: 2032-02-08→ Common Stock (4,189 underlying) - Sale
Common Stock
2025-02-10$59.34/sh−2,295$136,187→ 4,409 total - Exercise/Conversion
Common Stock
2025-02-11+2,031→ 6,440 total - Exercise/Conversion
Restricted Stock Units
2025-02-09−3,437→ 3,437 total→ Common Stock (3,437 underlying)
Footnotes (8)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2024.
- [F3]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $58.0750 to $58.8900 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- [F4]The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $59.1400 to $59.3600 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- [F5]The sales reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F6]The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
- [F7]The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
- [F8]The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.
Documents
Issuer
RHYTHM PHARMACEUTICALS, INC.
CIK 0001649904
Entity typeother
Related Parties
1- filerCIK 0001801372
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 9:46 PM ET
- Size
- 22.8 KB